Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Altered hypothalamic protein expression in a rat model of Huntington's disease.

Cong WN, Cai H, Wang R, Daimon CM, Maudsley S, Raber K, Canneva F, von Hörsten S, Martin B.

PLoS One. 2012;7(10):e47240. doi: 10.1371/journal.pone.0047240. Epub 2012 Oct 18. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/677c26e3-ce52-4837-853a-63c4ed7d72c0.

2.

Hypothalamic and neuroendocrine changes in Huntington's disease.

Hult S, Schultz K, Soylu R, Petersén A.

Curr Drug Targets. 2010 Oct;11(10):1237-49. Review.

PMID:
20594177
3.

Hypothalamic alterations in Huntington's disease patients: comparison with genetic rodent models.

van Wamelen DJ, Aziz NA, Roos RA, Swaab DF.

J Neuroendocrinol. 2014 Nov;26(11):761-75. doi: 10.1111/jne.12190. Review.

PMID:
25074766
4.

Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.

Martin B, Chadwick W, Cong WN, Pantaleo N, Daimon CM, Golden EJ, Becker KG, Wood WH 3rd, Carlson OD, Egan JM, Maudsley S.

J Biol Chem. 2012 Sep 14;287(38):31766-82. doi: 10.1074/jbc.M112.387316. Epub 2012 Jul 20.

5.

Hypothalamic-endocrine aspects in Huntington's disease.

Petersén A, Björkqvist M.

Eur J Neurosci. 2006 Aug;24(4):961-7. Epub 2006 Aug 21. Review.

PMID:
16925587
6.

Expression of mutant huntingtin in leptin receptor-expressing neurons does not control the metabolic and psychiatric phenotype of the BACHD mouse.

Lundh SH, Soylu R, Petersén A.

PLoS One. 2012;7(12):e51168. doi: 10.1371/journal.pone.0051168. Epub 2012 Dec 10.

7.

Transgenic rat model of Huntington's disease.

von Hörsten S, Schmitt I, Nguyen HP, Holzmann C, Schmidt T, Walther T, Bader M, Pabst R, Kobbe P, Krotova J, Stiller D, Kask A, Vaarmann A, Rathke-Hartlieb S, Schulz JB, Grasshoff U, Bauer I, Vieira-Saecker AM, Paul M, Jones L, Lindenberg KS, Landwehrmeyer B, Bauer A, Li XJ, Riess O.

Hum Mol Genet. 2003 Mar 15;12(6):617-24.

PMID:
12620967
8.

Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease.

Björkqvist M, Petersén A, Bacos K, Isaacs J, Norlén P, Gil J, Popovic N, Sundler F, Bates GP, Tabrizi SJ, Brundin P, Mulder H.

Hum Mol Genet. 2006 May 15;15(10):1713-21. Epub 2006 Apr 13.

PMID:
16613897
9.

Maintenance of basal levels of autophagy in Huntington's disease mouse models displaying metabolic dysfunction.

Baldo B, Soylu R, Petersén A.

PLoS One. 2013 Dec 20;8(12):e83050. doi: 10.1371/journal.pone.0083050. eCollection 2013.

10.

Weight loss in Huntington disease increases with higher CAG repeat number.

Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T; EHDI Study Group, Roos RA.

Neurology. 2008 Nov 4;71(19):1506-13. doi: 10.1212/01.wnl.0000334276.09729.0e.

PMID:
18981372
11.

Lack of huntingtin-associated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease.

Li SH, Yu ZX, Li CL, Nguyen HP, Zhou YX, Deng C, Li XJ.

J Neurosci. 2003 Jul 30;23(17):6956-64.

12.

Light and electron microscopic characterization of the evolution of cellular pathology in HdhQ92 Huntington's disease knock-in mice.

Bayram-Weston Z, Jones L, Dunnett SB, Brooks SP.

Brain Res Bull. 2012 Jun 1;88(2-3):171-81. doi: 10.1016/j.brainresbull.2011.03.013. Epub 2011 Apr 13.

PMID:
21513775
13.

Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1035-45.

14.

Towards a transgenic model of Huntington's disease in a non-human primate.

Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, Snyder B, Larkin K, Liu J, Orkin J, Fang ZH, Smith Y, Bachevalier J, Zola SM, Li SH, Li XJ, Chan AW.

Nature. 2008 Jun 12;453(7197):921-4. doi: 10.1038/nature06975. Epub 2008 May 18.

15.

Neurological abnormalities in a knock-in mouse model of Huntington's disease.

Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ.

Hum Mol Genet. 2001 Jan 15;10(2):137-44.

PMID:
11152661
16.

Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits.

Hult S, Soylu R, Björklund T, Belgardt BF, Mauer J, Brüning JC, Kirik D, Petersén Å.

Cell Metab. 2011 Apr 6;13(4):428-39. doi: 10.1016/j.cmet.2011.02.013.

17.

Early cognitive dysfunction in the HD 51 CAG transgenic rat model of Huntington's disease.

Fink KD, Rossignol J, Crane AT, Davis KK, Bavar AM, Dekorver NW, Lowrance SA, Reilly MP, Sandstrom MI, von Hörsten S, Lescaudron L, Dunbar GL.

Behav Neurosci. 2012 Jun;126(3):479-87. doi: 10.1037/a0028028.

PMID:
22642889
18.

Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.

Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P.

J Neurochem. 2001 Aug;78(4):694-703.

19.

Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.

Wyttenbach A, Swartz J, Kita H, Thykjaer T, Carmichael J, Bradley J, Brown R, Maxwell M, Schapira A, Orntoft TF, Kato K, Rubinsztein DC.

Hum Mol Genet. 2001 Aug 15;10(17):1829-45.

PMID:
11532992
20.

Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells.

Ribeiro M, Rosenstock TR, Cunha-Oliveira T, Ferreira IL, Oliveira CR, Rego AC.

Free Radic Biol Med. 2012 Nov 15;53(10):1857-67. doi: 10.1016/j.freeradbiomed.2012.09.004. Epub 2012 Sep 14.

PMID:
22982598

Supplemental Content

Support Center